Oscotec Inc.
Financials
Valuation Metrics
Oscotec Inc.'s Market Cap is ₩1.4T. At end of 2025 it was ₩1.7T. Ranked #250 of 2,405 in KR market (top 10%), #59 of 1,627 on KOSDAQ (top 4%), #26 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 11%) by Market Cap.
Investment Metrics(as of 2026-11-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.35T KRW | KR#250/2,405 Sec#26/231 |
| Revenue | 144.18B KRW | KR#1,207/2,405 Sec#73/231 |
| Net Income | 100.43B KRW | KR#251/2,405 Sec#14/231 |
| Total Assets | 267.18B KRW | KR#1,108/2,405 Sec#77/231 |
| Net Assets | 224.12B KRW | KR#884/2,405 Sec#62/231 |
| Employees | 51 | KR#2,035/2,405 Sec#188/231 |
| Value | ||
| P/E | 13.45x | KR#1,035/2,405 Sec#60/231 |
| P/B | 6.03x | KR#2,293/2,405 Sec#198/231 |
| PEG | 0.00x | KR#46/2,405 Sec#2/231 |
| P/S | 9.37x | KR#2,269/2,405 Sec#166/231 |
| EV/EBITDA | 14.91x | KR#901/2,405 Sec#53/231 |
| Profitability | ||
| ROE | 44.81% | KR#18/2,405 Sec#2/231 |
| ROA | 37.59% | KR#7/2,405 Sec#1/231 |
| Op. Margin | 62.23% | KR#4/2,405 Sec#1/231 |
| Revenue Growth | 232.64% | KR#30/2,405 Sec#8/231 |
| Earnings Growth | 4629.08% | KR#15/2,405 Sec#2/231 |
| Financial Health | ||
| Debt Ratio | 19.21% | KR#346/2,405 Sec#47/231 |
| Total Debt | 17.51B KRW | KR#1,421/2,405 Sec#116/231 |
| Cash | 32.39B KRW | KR#964/2,405 Sec#64/231 |
| Current Ratio | 6.09x | KR#208/2,405 Sec#42/231 |
| Net Debt/EBITDA | -0.17x | KR#575/2,405 Sec#34/231 |
| Performance | ||
| 1Y Return | -15.45% | KR#1,023/2,405 Sec#64/231 |
| 1M Return | -3.55% | KR#547/2,405 Sec#51/231 |
| From 52W High | -46.52% | KR#1,011/2,405 Sec#70/231 |
| 1Y MDD | -54.84% | KR#1,172/2,405 Sec#98/231 |
| Trading | ||
| Volume | 96,186 shares | KR#803/2,405 Sec#86/231 |
| Trading Value | 3.35B KRW | KR#393/2,405 Sec#34/231 |
| Foreign Own. | 12.30% | KR#402/2,405 Sec#30/231 |
| Per Share | ||
| EPS | 2,625 KRW | KR#381/2,405 Sec#25/231 |
| BPS | 5,858 KRW | KR#1,388/2,405 Sec#98/231 |
Company Info
Oscotec, a new drug development biotechnology company established in 1998, specializes in synthetic new drug development, building a differentiated business model through the commercialization of its research products. Its targeted anticancer lung cancer treatment received approval as a first-line treatment from the Korean Ministry of Food and Drug Safety and the U.S. FDA. The company's autoimmune disease treatment has applied for additional clinical trials after completing global Phase 2a for ITP disease, while its next-generation anticancer drug received U.S. FDA Phase 1 Investigational New Drug (IND) approval, and its Alzheimer's disease treatment is undergoing Phase 1 clinical trials in the U.S. Oscotec is headquartered in Seongnam-si, Gyeonggi-do.